INvestigating DIGital Outcomes in the Community
Launched by IMPERIAL COLLEGE LONDON · Oct 17, 2023
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "INvestigating DIGital Outcomes in the Community" is looking to understand how to best collect feedback from patients who have been treated for cancer and are now living in the community. This study will use an online questionnaire to gather information directly from patients about their experiences and health after treatment. The researchers want to explore how the order of questions might impact the responses, which will help improve future studies.
To participate, you need to be over 16 years old and have been diagnosed with cancer at least 12 months ago. You don’t need to be currently receiving treatment to join, but you should be able to access a secure online platform to complete the questionnaire. It’s important that you can understand and read English, but you can get help from someone you trust if needed. The trial is not currently recruiting participants, but it aims to gather valuable insights that could benefit cancer survivors in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Anyone over the age of 16 who has been diagnosed (receiving treatment is not an inclusion criteria although the investigators expect as this is a long-term survivorship study all participants will have received treatment) for any type of cancer in the past (\> 12 months) can participate.
- • Participants who self-identify as having previously (time unlimited) received a diagnosis of cancer, based on histological, radiological, or clinical grounds (primary and/or metastatic cancer). Current treatment is not a barrier to participation, but the emphasis is on patients who have completed treatment.
- • Participants need to be able to access the secure online platform, using a mobile device or computer.
- • Have capacity and be able to provide informed consent via the online platform.
- • To be able to understand, read and write English, with or without support from a trusted individual e.g., friends, family, carer.
- Exclusion Criteria:
- • Participants recently diagnosed with cancer (less than 12 months ago).
- • Participants unable to access secure online platform.
- • Participants who do not have sufficiently good understanding of written English to complete the PROMs and are unable to be supported by a trusted individual to complete the questionnaire.
- • Participants lacking capacity and unable to give informed consent.
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Matthew Williams, MBChB PhD FRCR
Principal Investigator
Imperial College Healthcare Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported